ERBB2 and breast cancer: In summary, our findings provide a rationale for the pre-clinical development of G28UCM either alone or in combination with anti-HER agents (trastuzumab, lapatinib, erlotinib, gefitinib or cetuximab) in HER2-overexpressing breast cancer.